Bbt-401-1s    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
97潰瘍性大腸炎4

97. 潰瘍性大腸炎 [臨床試験数:2,269,薬物数:1,331(DrugBank:241),標的遺伝子数:114,標的パスウェイ数:181
Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 2,269 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04596293
(ClinicalTrials.gov)
January 31, 202115/10/2020Efficacy and Safety of Orally Administered BBT-401-1S in Subjects With Ulcerative ColitisA Randomised, Double-blind, Placebo-controlled Study of Orally Administered BBT-401-1S in Subjects With Moderate to Severe Ulcerative Colitis, Incorporating a Response-adaptive, Double-blind Extension PhaseUlcerative ColitisDrug: BBT-401-1S;Drug: PlaceboBridge Biotherapeutics, Inc.CovanceNot yet recruiting18 Years60 YearsAll36Phase 2NULL
2NCT04478825
(ClinicalTrials.gov)
October 30, 202016/7/2020Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative ColitisAn Open Label, Proof of Mechanism Study to Explore the Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative ColitisUlcerative ColitisDrug: BBT-401-1SBridge Biotherapeutics, Inc.CovanceRecruiting18 Years60 YearsAll6Phase 1New Zealand
3NCT03800420
(ClinicalTrials.gov)
April 22, 20197/1/2019Efficacy and Safety of BBT-401-1S in Ulcerative ColitisA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of BBT-401-1S in Patients With Active Ulcerative ColitisUlcerative ColitisDrug: Active group;Drug: Placebo groupBridge Biotherapeutics, Inc.KCRN Research, LLCTerminated18 YearsN/AAll16Phase 2United States
4NCT03482648
(ClinicalTrials.gov)
March 20, 201817/3/2018First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy VolunteersA Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Novel Oral Peptide BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Adult SubjectsUlcerative ColitisDrug: BBT-401-1S, Single dose;Drug: BBT-401-1S, Multiple doses;Drug: PlaceboBridge Biotherapeutics, Inc.KCRN Research, LLCCompleted19 Years55 YearsAll80Phase 1United States